Sonidegib (LDE225), an SMO antagonist, has earned FDA clearance [72,73], championed by its notable efficacy in treating advanced and metastatic basal cell carcinoma, as demonstrated by Dummer et al. Vismodegib (GDC-0449), another antagonist of SMO, also delivered promising outcomes in metastatic basal cell carcinoma and received FDA approval [74,75]. Here, SMO is linked to basal cell carcinoma.